Sermorelin vs Ipamorelin vs Tesamorelin: Which Fits?

Quick Answer by Goal

If you have already narrowed it to these three, here is the short version before the detail. Want to lose deep abdominal fat? Tesamorelin has the direct data. Want the cleanest side-effect profile and recovery support? Ipamorelin (usually paired with CJC-1295). Want the most natural signaling, a conservative first step, or the lowest cost? Sermorelin. The rest of this guide explains why each of those is true, and where the honest caveats are.

The Three at a Glance

That table is the map. Below is the terrain. If you want a full head-to-head on any single pair, we have dedicated deep-dives: Ipamorelin vs Sermorelin, CJC-1295 vs Sermorelin, and Tesamorelin vs CJC-1295.

Two Pathways, One Goal

Your pituitary releases growth hormone in pulses, with the biggest pulse during deep sleep. Two upstream signals drive those pulses. GHRH (growth-hormone-releasing hormone) comes from the hypothalamus and tells the pituitary to fire. Ghrelin, mostly from the stomach, amplifies that firing through a separate receptor. Every peptide here works one of those two levers.

Sermorelin and tesamorelin are both GHRH analogs. They bind the GHRH receptor and trigger a growth hormone pulse that looks like your natural one. The difference between them is durability: tesamorelin is a chemically stabilized version that resists the enzymes that chew up native GHRH, so it lasts longer and hits harder. Sermorelin is the plain, short-acting original.

Ipamorelin is the odd one out. It is a small five-amino-acid peptide that binds the ghrelin receptor instead. What makes it notable is selectivity. Earlier ghrelin-pathway compounds also spiked cortisol, prolactin, and hunger. Ipamorelin was the first one characterized that raised growth hormone cleanly, without meaningfully moving those other hormones.

Raun K et al., "Ipamorelin, the first selective growth hormone secretagogue," European Journal of Endocrinology, 1998;139(5):552-561. View study

This is why the two pathways are complementary, not competing. Pushing the GHRH lever and the ghrelin lever at the same time produces more growth hormone than either alone. Hold that thought for the "why they are often combined" section below.

Sermorelin: the First-Line GHRH Analog

Sermorelin is a 29-amino-acid copy of the active fragment of your own GHRH. Because it is essentially your natural signal, it produces the most physiologic pulse of the three and rarely surprises people. It also carries the longest clinical history: it was FDA-approved in the 1990s (brand name Geref) for diagnosing and treating growth hormone deficiency in children, then discontinued commercially, not for safety reasons.

Prakash A, Goa KL, "Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency," BioDrugs, 1999;12(2):139-157. View study

In practice, sermorelin is the conservative starting point. It is the least expensive of the three, it respects your natural feedback brakes (so it is hard to push into a runaway state), and it is a sensible way to find out how you respond to a growth hormone peptide before considering anything stronger. Most people notice sleep quality first. For the full profile, see the Sermorelin guide.

Ipamorelin: the Selective One

Ipamorelin’s whole reputation is built on what it does not do. It triggers a clean growth hormone pulse without the cortisol spike that promotes fat storage and disrupts sleep, and without the prolactin bump that can cause water retention. That selectivity is why it became the preferred ghrelin-pathway peptide in clinical use.

The catch is that ipamorelin is short-lived on its own, so it is almost never prescribed by itself. The standard is to pair it with a longer-acting GHRH analog, most often CJC-1295. That combination gives you a sustained baseline of GH signaling from the CJC-1295 with a sharp, clean pulse layered on top from the ipamorelin. If you want ipamorelin, you are almost certainly looking at CJC-1295/Ipamorelin, and it is worth reading why we pair them.

Tesamorelin: the FDA-Approved One

Tesamorelin is the only peptide in this comparison with a current FDA approval. Under the brand name Egrifta, it is approved to reduce excess abdominal fat in people with HIV-associated lipodystrophy. That approval matters because it means tesamorelin cleared a full clinical trial program, which none of the others did.

In its pivotal 26-week trial, tesamorelin reduced visceral adipose tissue (the deep fat around the organs) by about 15 percent, compared with a slight increase on placebo, while raising IGF-1. That is a specific, measured effect on a specific fat depot, which is why tesamorelin is the go-to when the goal is deep abdominal fat rather than general body composition.

Falutz J et al., "Metabolic effects of a growth hormone-releasing factor in patients with HIV," New England Journal of Medicine, 2007;357(23):2359-2370. View study

For the deeper profile, see the Tesamorelin guide.

Half-Life and the GH Pulse

Half-life is not trivia here. It shapes how big and how sustained the growth hormone pulse is, and how often you dose. Sermorelin clears fastest, in roughly 10 to 12 minutes, producing a quick, natural-looking pulse. Tesamorelin is chemically stabilized to resist breakdown, extending its half-life to about 26 to 38 minutes, which is part of why it produces a stronger effect. Ipamorelin is longer-acting than the GHRH analogs.

Because all three are short-acting relative to a daily rhythm, they are typically injected at night on a relatively empty stomach, so the induced pulse lands during early deep sleep when your largest natural pulse already fires. Carbohydrate and insulin blunt the response, which is the reason for the timing. Your provider sets the actual dose and schedule.

Choose by Your Goal

The cleanest way to decide is to start from what you actually want, not from which peptide sounds strongest.

Goal: reduce deep abdominal fat

Tesamorelin is the answer here, and it is not close. It is the only one of the three with direct, measured visceral-fat data and an FDA approval built on it. If a shrinking waistline driven by deep visceral fat is the priority, this is the peptide with the evidence.

Goal: recovery, lean mass, and a clean profile

Ipamorelin (as CJC-1295/Ipamorelin) is the usual pick. The selectivity means no cortisol drag on recovery or sleep, and the CJC-1295 pairing sustains the GH signal long enough to support tissue repair and body composition. This is the most common growth hormone peptide protocol in telehealth for a reason.

Goal: natural signaling, sleep, or a conservative first step

Sermorelin fits. It is the closest thing to turning your own GHRH signal up a notch, it is the least expensive, and it is the sensible way to test your response before escalating. Many people run sermorelin first and only move to a stronger option if their goals or results call for it.

Why They Are Often Combined

The framing of "which one" is a little misleading, because the most effective growth hormone protocols usually combine two levers rather than pick one. A GHRH analog plus a ghrelin agonist produces a growth hormone release larger than the sum of either given alone. This was shown decades ago in healthy men and is the entire logic behind pairing CJC-1295 with ipamorelin.

Bowers CY et al., "Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone," Journal of Clinical Endocrinology and Metabolism, 1990;70(4):975-982. View study

What providers do not typically do is stack two GHRH analogs together. Sermorelin plus tesamorelin would be redundant, because they hit the same receptor. The productive combinations pair a GHRH analog (sermorelin, tesamorelin, or CJC-1295) with the ghrelin agonist (ipamorelin), which is why CJC-1295/Ipamorelin and Tesamorelin/Ipamorelin exist as combination products.

Side Effects and Cost

All three are well-tolerated, and the most common side effect for any of them is mild injection-site irritation. Beyond that, the profiles diverge along the same pathway logic. Sermorelin and tesamorelin (the GHRH analogs) can cause transient facial flushing and occasional headache. Ipamorelin rarely flushes, and because it does not raise cortisol or prolactin, it avoids the downstream effects tied to those hormones. Any growth hormone peptide can cause temporary water retention or hand tingling in the first week or two as GH levels rise, which settles as the body adjusts.

On cost, sermorelin and tesamorelin are both $229 a month at PeRx, and CJC-1295/Ipamorelin is $299 a month. Ipamorelin is not sold on its own here, because it is not clinically used on its own. All three are prescription-only, dispensed as ready-to-use vials after a provider reviews your intake and, where appropriate, your labs.

Frequently Asked Questions

Reviewed by Dr. Cory Mellon, MD · Last reviewed July 2026